PRIMARY STUDY

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis

Key Findings:  This mouse model of gastric inflammation finds that selective CB2 agonists have effective anti-inflammatory properties, and could lead to further development of targeted treatments for diseases such as inflammatory bowel disease (IBD).